keyword
MENU ▼
Read by QxMD icon Read
search

safinamide

keyword
https://www.readbyqxmd.com/read/29760163/%C3%A2-safinamide-for-parkinson-s-disease
#1
(no author information available yet)
▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson's disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29670409/safinamide-an-add-on-treatment-for-managing-parkinson-s-disease
#2
REVIEW
Thomas Müller
Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson's disease. Intervals, characterized by reappearance of motor and associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of oral levodopa therapy. These "OFF" states result from levodopa pharmacokinetics and disease progression-related deterioration of the central buffering capacity for fluctuations of dopamine levels. This review discusses safinamide as an add-on therapeutic agent in orally levodopa-treated patients with "OFF" phenomena...
2018: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/29609697/2018-new-drug-update
#3
Daniel A Hussar, Laura A Finn
Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation...
April 1, 2018: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/29570866/international-parkinson-and-movement-disorder-society-evidence-based-medicine-review-update-on-treatments-for-the-motor-symptoms-of-parkinson-s-disease
#4
REVIEW
Susan H Fox, Regina Katzenschlager, Shen-Yang Lim, Brandon Barton, Rob M A de Bie, Klaus Seppi, Miguel Coelho, Cristina Sampaio
OBJECTIVE: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). BACKGROUND: The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016. METHODS: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported...
March 23, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29570862/medical-and-surgical-management-of-advanced-parkinson-s-disease
#5
REVIEW
Angelo Antonini, Elena Moro, Clecio Godeiro, Heinz Reichmann
Advanced Parkinson's disease is characterized by the presence of motor fluctuations, various degree of dyskinesia, and disability with functional impact on activities of daily living and independence. Therapeutic management aims to extend levodopa benefit while minimizing motor complications and includes, in selected cases, the implementation of drug infusion and surgical techniques. In milder forms of motor complications, these can often be controlled with manipulation of levodopa dose and the introduction of supplemental therapies such as catechol-O-methyl transferase inhibitors, monoamine oxidase B inhibitors, and dopamine agonists including apomorphine...
March 23, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29542008/long-term-efficacy-of-safinamide-on-parkinson-s-disease-chronic-pain
#6
Carlo Cattaneo, Jaime Kulisevsky, Viviana Tubazio, Paola Castellani
INTRODUCTION: Chronic pain is an important yet overlooked non-motor symptom of Parkinson's disease (PD), caused by an imbalance of the dopaminergic and glutamatergic systems. Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms. OBJECTIVES: To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment...
March 14, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29464559/monoamine-oxidases
#7
Dale E Edmondson, Claudia Binda
Monoamine oxidases A and B (MAO A and B) are mammalian flavoenzymes bound to the outer mitochondrial membrane. They were discovered almost a century ago and they have been the subject of many biochemical, structural and pharmacological investigations due to their central role in neurotransmitter metabolism. Currently, the treatment of Parkinson's disease involves the use of selective MAO B inhibitors such as rasagiline and safinamide. MAO inhibition was shown to exert a general neuroprotective effect as a result of the reduction of oxidative stress produced by these enzymes, which seems to be relevant also in non-neuronal contexts...
2018: Sub-cellular Biochemistry
https://www.readbyqxmd.com/read/29441484/real-life-evaluation-of-safinamide-effectiveness-in-parkinson-s-disease
#8
Francesca Mancini, Alessio Di Fonzo, Giulia Lazzeri, Linda Borellini, Vincenzo Silani, Marco Lacerenza, Cristoforo Comi
In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD)...
April 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29339106/safinamide-a-new-hope-for-parkinson-s-disease
#9
REVIEW
Fábio G Teixeira, Miguel F Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa, António J Salgado
The loss of dopaminergic neurons (DAn) and reduced dopamine (DA) production underlies the reasoning behind the gold standard treatment for Parkinson's disease (PD) using levodopa (L-DOPA). Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. In addition, nondopaminergic actions (neuroprotective effects) have been reported, with safinamide inhibiting glutamate release and sodium/calcium channels, reducing the excitotoxic input to dopaminergic neuronal death...
March 2018: Drug Discovery Today
https://www.readbyqxmd.com/read/29290341/safinamide-mesylate-brodalumab-guselkumab-and-abaloparatide
#10
Daniel A Hussar, Mariya Kotova
No abstract text is available yet for this article.
January 2018: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/29276285/formulary-drug-review-safinamide
#11
REVIEW
Danial E Baker, Anne P Kim
No abstract text is available yet for this article.
September 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29198609/synthesis-and-evaluation-of-biaryl-derivatives-for-structural-characterization-of-selective-monoamine-oxidase-b-inhibitors-toward-parkinson-s-disease-therapy
#12
Seul Ki Yeon, Ji Won Choi, Jong-Hyun Park, Ye Rim Lee, Hyeon Jeong Kim, Su Jeong Shin, Bo Ko Jang, Siwon Kim, Yong-Sun Bahn, Gyoonhee Han, Yong Sup Lee, Ae Nim Pae, Ki Duk Park
Benzyloxyphenyl moiety is a common structure of highly potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B), safinamide and sembragiline. We synthesized 4-(benzyloxy)phenyl and biphenyl-4-yl derivatives including halogen substituents on the terminal aryl unit. In addition, we modified the carbon linker between amine group and the biaryl linked unit. Among synthesized compounds, 12c exhibited the most potent and selective MAO-B inhibitory effect (hMAO-B IC50 : 8.9 nM; >10,000-fold selectivity over MAO-A) as a competitive inhibitor...
January 1, 2018: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29176433/drug-updates-and-approvals-2017-in-review
#13
Geoffrey Mospan, Cortney Mospan, Shayna Vance, Alyssa Bradshaw, Kalyn Meosky, Kirklin Bowles
In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).
December 15, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/29167350/safinamide-differentially-modulates-in-vivo-glutamate-and-gaba-release-in-the-rat-hippocampus-and-basal-ganglia
#14
Michele Morari, Alberto Brugnoli, Clarissa Anna Pisanò, Salvatore Novello, Carla Caccia, Elsa Melloni, Gloria Padoani, Silvia Vailati, Marco Sardina
Safinamide has been recently approved as an add-on to levodopa therapy for Parkinson disease. In addition to inhibiting monoamine oxidase type B, it blocks sodium channels and modulates glutamate (Glu) release in vitro. Since this property might contribute to the therapeutic action of the drug, we undertook the present study to investigate whether safinamide inhibits Glu release also in vivo and whether this effect is consistent across different brain areas and is selective for glutamatergic neurons. To this aim, in vivo microdialysis was used to monitor the spontaneous and veratridine-induced Glu and GABA release in the hippocampus and basal ganglia of naive, awake rats...
February 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29130466/-safinamide-from-daily-clinical-practice-first-clinical-steps
#15
J Pagonabarraga, J Kulisevsky
INTRODUCTION: The management of motor complications in Parkinson's disease (PD) is still limited. Safinamide, a new drug that has MAO-B inhibition and antiglutamatergic effects through inhibition of sodium channels, has shown efficacy for the treatment of fluctuations at doses of 50-100 mg/day. PATIENTS AND METHODS: From daily clinical practice, we describe the efficacy and tolerability of safinamide at three months in PD patients with motor complications. Efficacy was assessed by the Clinical Global Impression of Change scale and change in 'off' time during the daytime...
November 16, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/29018297/xadago-safinamide-a-monoamine-oxidase-b-inhibitor-for-the-adjunct-treatment-of-motor-symptoms-in-parkinson-s-disease
#16
Martin Paspe Cruz
Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson's disease.
October 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28880847/safinamide-xadago-for-parkinson-s-disease
#17
(no author information available yet)
No abstract text is available yet for this article.
September 11, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28796020/hypersexuality-possibly-associated-with-safinamide
#18
Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Dolores Valle-Arcos
No abstract text is available yet for this article.
August 8, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28777756/long-term-effects-of-safinamide-on-mood-fluctuations-in-parkinson-s-disease
#19
Carlo Cattaneo, Thomas Müller, Erminio Bonizzoni, Gabriele Lazzeri, Ioannis Kottakis, Charlotte Keywood
BACKGROUND: Mood disorders are very frequent in Parkinson's Disease (PD), and their effective treatment is still a major unresolved issue: growing evidence suggests that glutamatergic system dysfunction is directly involved. Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels...
2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/28682929/determination-of-monoamine-oxidase-a-and-b-activity-in-long-term-treated-patients-with-parkinson-disease
#20
Thomas Müller, Peter Riederer, Edna Grünblatt
BACKGROUND: Biogenic amines and monoamine oxidase inhibitors influence peripheral monoamine oxidase enzyme activity in chronic levodopa/dopa decarboxylase inhibitor-treated patients with Parkinson disease. Rasagiline is an irreversible inhibitor of monoamine oxidase B. Safinamide blocks this isoenzyme in a reversible fashion. OBJECTIVES: The aim of this study was to determine monoamine oxidase A (plasma) and B (platelets) enzyme activity in long-term levodopa-treated patients without and with additional oral intake of 50- or 100-mg safinamide or 1-mg rasagiline or first-time intake of rasagiline...
September 2017: Clinical Neuropharmacology
keyword
keyword
94106
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"